Picture loading failed.

Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order information


Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-645-1mg 1mg Inquiry
GMP-Bios-ab-645-10mg 10mg Inquiry
GMP-Bios-ab-645-100mg 100mg Inquiry
GMP-Bios-ab-645-xmg >100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Zenocutuzumab biosimilar, Bispecific mAb, Anti-ERBB3/Erbb-3;ERBB2/HER2 Antibody: Anti-FERLK/HER3/LCCS2/MDA-BF-1/VSCN1/c-erbB3/erbB3-S/p180-ErbB3/p45-sErbB3/p85-sErbB3;CD340/neu/MLN 19/NEU/NGL/TKR1/VSCN2 therapeutic antibody
INN Name Zenocutuzumab
TargetErbb-3;HER2
FormatBispecific mAb
DerivationBispecific antibody
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa;Kappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI Structure5o4o:BA/5o7p:BA;5o4g:BA
99% SI StructureNone;None
95-98% SI StructureNone;None
Year Proposed2017
Year Recommended2018
CompaniesMerus
Conditions Approvedna
Conditions ActiveBreast cancer;Colorectal cancer;Gastric cancer;Non-small cell lung cancer
Conditions DiscontinuedEndometrial cancer;Ovarian cancer
Development TechGlymaxX Technology